Bots, Steven J. http://orcid.org/0000-0003-2017-2857
Parker, Claire E.
Brandse, Johannan F.
Löwenberg, Mark
Feagan, Brian G.
Sandborn, William J.
Jairath, Vipul
D’Haens, Geert
Vande Casteele, Niels
Funding for this research was provided by:
American Gastroenterological Association (Research Scholar Award)
National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK120515, P30 DK120515)
Article History
Accepted: 23 October 2021
First Online: 19 November 2021
Declarations
:
: NVC holds a Research Scholar Award from the American Gastroenterological Association. WJS and NVC are supported in part by the NIDDK-funded San Diego Digestive Diseases Research Center (P30 DK120515).
: SB has served as speaker for Abbvie, Merck, Sharp & Dome, Takeda, Jansen Cilag, Pfizer and Tillotts. CEP is an employee of Robarts Clinical Trials, Inc. JFB has served as speaker for Abbvie, Merck, Sharp & Dome, Takeda and Tillotts. ML has served as speaker and/or principal investigator for Abbvie, Celgene, Covidien, Dr Falk, Ferring Pharmaceuticals, Gilead, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Protagonist Therapeutics, Receptos, Takeda, Tillotts, Tramedico. He has received research grants from AbbVie, Merck Sharp & Dohme, Achmea Healthcare and ZonMW. BGF has received grant/research support from Millennium Pharmaceuticals, Merck, Tillotts Pharma AG, AbbVie, Novartis Pharmaceuticals, Centocor Inc., Elan/Biogen, UCB Pharma, Bristol-Myers Squibb, Genentech, ActoGeniX and Wyeth Pharmaceuticals Inc.; consulting fees from Millennium Pharmaceuticals, Merck, Centocor Inc., Elan/Biogen, Janssen-Ortho, Teva Pharmaceuticals, Bristol-Myers Squibb, Celgene, UCB Pharma, AbbVie, Astra Zeneca, Serono, Genentech, Tillotts Pharma AG, Unity Pharmaceuticals, Albireo Pharma, Given Imaging Inc., Salix Pharmaceuticals, Novonordisk, GSK, ActoGeniX, Prometheus Therapeutics and Diagnostics, Athersys, Axcan, Gilead, Pfizer, Shire, Wyeth, Zealand Pharma, Zyngenia, gIcare Pharma Inc. and Sigmoid Pharma; and speaker bureau fees from UCB, AbbVie and J&J/Janssen. WJS has received research grants from Abbvie, Abivax, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene, Genentech, Gilead Sciences, Glaxo Smith Kline, Janssen, Lilly, Pfizer, Prometheus Biosciences, Seres Therapeutics, Shire, Takeda, Theravance Biopharma; consulting fees from Abbvie, Abivax, AdMIRx, Alfasigma, Alimentiv (previously Robarts Clinical Trials, owned by Alimentiv Health Trust), Alivio Therapeutics, Allakos, Amgen, Applied Molecular Transport, Arena Pharmaceuticals, Bausch Health (Salix), BeiGene, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Celgene, Celltrion, Cellularity, Cosmo Pharmaceuticals, Escalier Biosciences, Equillium, Forbion, Genentech/Roche, Gilead Sciences, Glenmark Pharmaceuticals, Gossamer Bio, Immunic (Vital Therapies), Index Pharmaceuticals, Intact Therapeutics, Janssen, Kyverna Therapeutics, Landos Biopharma, Lilly, Oppilan Pharma, Otsuka, Pandion Therapeutics, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonists Therapeutics, Provention Bio, Reistone Biopharma, Seres Therapeutics, Shanghai Pharma Biotherapeutics, Shire, Shoreline Biosciences, Sublimity Therapeutics, Surrozen, Takeda, Theravance Biopharma, Thetis Pharmaceuticals, Tillotts Pharma, UCB, Vendata Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivelix Pharmaceuticals, Vivreon Biosciences, Zealand Pharma; stock or stock options from Allakos, BeiGene, Gossamer Bio, Oppilan Pharma, Prometheus Biosciences, Prometheus Laboratories Progenity, Shoreline Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivreon Biosciences; and is an employee at Shoreline Biosciences. Spouse: Iveric Bio (consultant, stock options); Progenity (stock); Oppilan Pharma (consultant, stock options); Prometheus Biosciences (employee, stock, stock options); Prometheus Laboratories (stock, stock options, consultant); Ventyx Biosciences (stock, stock options); Vimalan Biosciences (stock, stock options). VJ has received scientific advisory board fees from Janssen, Takeda, Pfizer, Sandoz, Abbvie and Merck; and speaker bureaux fees from Takeda, Ferring, Janssen, Pfizer and Shire. GDH has served as advisor for Abbvie, Ablynx, Allergan, Amakem, Amgen, AM Pharma, Arena Pharmaceuticals, AstraZeneca, Avaxia, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene/Receptos, Celltrion, Cosmo, Covidien/Medtronic, Ferring, Dr Falk Pharma, Eli Lilly, enGene, Galapagos, Genentech/Roche, Gilead, Glaxo Smith Kline, Hospira/Pfizer, Immunic, Johnson and Johnson, Lycera, Medimetrics, Millenium/Takeda, Mitsubishi Pharma, Merck Sharp & Dome, Mundipharma, Nextbiotics, Novonordisk, Otsuka, Pfizer/Hospira, Photopill, Prometheus laboratories/Nestle, Progenity, Protagonist, Robarts Clinical Trials, Salix, Samsung Bioepis, Sandoz, Seres/Nestle, Setpoint, Shire, Teva, TiGenix, Tillotts, Topivert, Versant and Vifor; received speaker fees from Abbvie, Biogen, Ferring, Johnson and Johnson, Merck Sharp & Dome, Mundipharma, Norgine, Pfizer, Samsung Bioepis, Shire, Millenium/Takeda, Tillotts and Vifor. NVC has received research grants and personal fees from R-Biopharm, Takeda and UCB; and personal fees from Alimentiv, Inc. (formerly Robarts Clinical Trials, Inc.), Celltrion and Prometheus.
: All data will be made available.
: No funding was received for writing assistance.
: Study concept and design: SB, GDH, NVC; acquisition of data: SB, JFB, NVC; analysis and interpretation of data: SB, CEP, NVC; draft of the manuscript: SB, CEP, NVC; critical revision of the manuscript for important intellectual content: SB, JFB, ML, BGF, WJS, RK, VJ, GDH, NVC; study supervision: GDH, NVC. All authors have approved the final version of this manuscript.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.